A Single-Dose, Randomized, Double-Blind, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Adult Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 20 Feb 2016
At a glance
- Drugs BIIB 023 (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Biogen
- 20 Feb 2016 Results published in the British Journal of Clinical Pharmacology
- 15 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.